SUMMARY Results from British trials of phenobarbitone and valproate for the prophylactic treatment of febrile convulsions were pooled and analysed on an intention to treat basis. The overall odds ratio for phenobarbitone was 0-8 and for valproate 1 42. Neither result was significant. Neither treatment can be recommended in the light of experience.
Controlled trials of drug treatment are usually pragmatic studies of treatment practice, and analysis should then be on an intention to treat basis. The question being asked is whether the intention to treat a population of children with febrile fits with anticonvulsants reduces the risk of recurrence relative to that in a control group. Many trials have excluded children from analysis who did not take their medication through either poor adherence to instructions or side effects. Analysis on this basis answers the question of whether risk of recurrence is reduced in quite a selected population which is difficult to define in advance.
Analysis on an intention to treat basis demands that children are analysed with the group to which they were originally allocated. Invariably some children are lost to follow up and available resources make this difficult to overcome. An assumption is usually made in the analysis that no bias has been introduced through this happening. Studies have shown apparently conflicting results. This is often due to small study groups either exaggerating or overlooking clinical benefit due to the play of chance. Pooled analysis leaves less to the play of chance by increasing the study population size. The method used is similar to that used in multicentre trials. Within centre differences between study and control groups become within study differences that are estimated and then pooled. An overall odds ratio (relative risk) is provided. This is the risk of recurrence in the treatment group relative to controls. An odds ratio of unity thus will signify no difference. An odds ratio of less than unity suggests some treatment benefit; greater than unity no benefit. When the odds ratio and its 95% confidence interval lie entirely to one side of unity the result is significant at p<05.
The method assumes data from all trials are available. None must be omitted because they showed negative results and were therefore unpublished. The method does not assume that one trial is directly comparable with another, but does assume the true odds ratio to be the same for each.
Method
Statistical analysis was identical to that used by The table summarises data from the trials.
Trials were identified through a computerised literature search. Those unpublished were identified by writing to all members of the British Paediatric Neurology Association and paediatricians known to have participated in such work.
Children were reallocated to the groups to which they were originally assigned before reanalysis of data. Details were usually available from the paper itself or clarification was sought from the authors.
Data in all but one paper can be confirmed.7
Results
The numbers in each trial and recurrences in each study group are summarised in the table. The pooled analysis of the phenobarbitone and valproate trials is summarised in the figure.
For phenobarbitone the odds ratio varied from 0.426 to 2-077: in two it was less than unity and in four greater. The overall odds ratio for the 535 children was 0-8 (95% confidence interval: 0-53 to 1.20) a non-significant result. Sixty six of the 296 (22%) treated children had recurrences compared with 58 of 236 (25%) controls. 1189 
